Optimizing Partnerships for Generic Drug Development Success

The generic drug industry, accounting for over 90% of all US prescriptions, is increasingly reliant on strategic scaling, supply chain optimization, and portfolio management. Manufacturers should focus on multisourcing programs, domestic production for high-volume products, and high-value products with established channels. Collaborations with other organizations can promote innovation. Real-world data is also vital for enhancing drug value and patient outcomes. Despite a competitive market and rising costs, strategic partnerships and efficient supply chain management can offer opportunities for growth and innovation.